Methods and compositions for detecting colon cancers
View Patent ↗This application describes methods and compositions for detecting and treating vimentin-associated neoplasia. Differential methylation of the vimentin nucleotide sequences has been observed in vimentin-associated neoplasia such as colon neoplasia.
1. A method for detecting the likelihood that a human patient has colon neoplasia, comprising:
a) obtaining a sample from a human patient; and
b) assaying said sample for the presence or absence of methylation within a nucleotide sequence selected from the group consisting of SEQ ID NOs: 40-45, wherein the presence of methylation within any one of said nucleotide sequence is indicative of the likelihood that the human patient has colon neoplasia.
2. The method of claim 1 , wherein the sample is a bodily fluid selected from the group consisting of blood, serum, plasma, a blood-derived fraction, stool, urine, and a colonic effluent.
3. The method of claim 2 , wherein the bodily fluid is obtained from a subject suspected of having or is known to have colon neoplasia.
4. The method of claim 1 , wherein said colon neoplasia is colon cancer.
5. The method of claim 1 , comprising assaying for the presence of methylation of the vimentin sequence of SEQ ID NO: 45.
6. The method of claim 1 , comprising assaying for the presence of methylation of a vimentin sequence selected from SEQ ID NOs: 40-43.
7. The method of any of claims 1 - 3 , wherein the assay is methylation-specific PCR.
8. The method of claim 7 , comprising:
a) treating DNA from the sample with a compound that converts non-methylated cytosine bases in the DNA to a different base;
b) amplifying a region of the compound converted vimentin nucleotide sequence with a forward primer and a reverse primer; and
c) analyzing the methylation patterns of said vimentin nucleotide sequences.
9. The method of claim 7 , comprising:
a) treating DNA from the sample with a compound that converts non-methylated cytosine bases in the DNA to a different base;
b) amplifying a region of the compound converted vimentin nucleotide sequence with a forward primer and a reverse primer; and
c) detecting the presence and/or amount of the amplified product.
10. The method of claim 8 , wherein the compound used to treat DNA is a bisulfite compound.
11. The method of any of claims 1 - 3 , wherein the assay comprises using a methylation-specific restriction enzyme.
12. The method of claim 11 , wherein said methylation-specific restriction enzyme is selected from HpaII, SmaI, SacII, EagI, MspI, BstUI, and BssHII.
13. A method for detecting the likelihood that a human subject has colon neoplasia, comprising detecting vimentin protein or nucleic acid expression level in a sample from the human subject, wherein reduced expression level of vimentin protein or nucleic acid relative to a control sample from a healthy subject is indicative of the likelihood that the human subject has colon neoplasia.
14. The method of claim 13 , wherein the sample is a bodily fluid selected from the group consisting of blood, serum, plasma, a blood-derived fraction, stool, urine, and a colonic effluent.
15. The method of claim 14 , wherein the bodily fluid is from a subject suspected of having or known to have colon neoplasia.
16. The method of claim 13 , wherein the vimentin protein is detected by immunoassays.
17. A method for monitoring over time colon neoplasia in a human subject, comprising:
a) detecting the methylation status of a vimentin nucleotide sequence selected from the group consisting of SEQ ID NOs: 40-45 in a sample from the human subject for a first time; and
b) detecting the methylation status of any one of said vimentin nucleotide sequence of step (a) in a sample from the same human subject at a later time;
wherein absence of methylation in the vimentin nucleotide sequence taken at a later time and presence of methylation in the vimentin nucleotide sequence taken at the first time is indicative of regression of colon neoplasia;
wherein presence of methylation in the vimentin nucleotide sequence taken at a later time and absence of methylation in the vimentin nucleotide sequence taken at the first time is indicative of progression of colon neoplasia.
18. The method of claim 17 , wherein the sample is a bodily fluid selected from the group consisting of blood, serum, plasma, a blood-derived fraction, stool, urine, and a colonic effluent.
19. A method for detecting the likelihood that a patient has colon neoplasia, comprising:
a) obtaining a sample from a patient; and
b) assaying said sample for the presence or absence of methylation within nucleotide sequence SEQ ID NO: 2, wherein the presence of methylation within said nucleotide sequence is indicative of the likelihood that the patient has colon neoplasia.
20. The method of claim 19 , wherein the sample is a bodily fluid selected from the group consisting of blood, serum, plasma, a blood-derived fraction, stool, urine, and a colonic effluent.
21. The method of claim 19 , wherein said colon neoplasia is colon cancer.
22. The method of claims 19 or 20 , wherein the assay is methylation-specific PCR.
23. The method of claim 22 , comprising:
a) treating DNA from the sample with a compound that converts non-methylated cytosine bases in the DNA to a different base;
b) amplifying a region of the compound converted vimentin nucleotide sequence with a forward primer and a reverse primer; and
c) analyzing the methylation patterns of said vimentin nucleotide sequences.
24. The method of claim 22 , comprising:
a) treating DNA from the sample with a compound that converts non-methylated cytosine bases in the DNA to a different base;
b) amplifying a region of the compound converted vimentin nucleotide sequence with a forward primer and a reverse primer; and
c) detecting the presence and/or amount of the amplified product.
25. The method of claim 22 , wherein the compound used to treat DNA is a bisulfite compound.